Vertex pays AbCellera $28M upfront for autoimmune T-cell engagers
AbCellera announced July 29 a collaboration with Vertex Pharmaceuticals to discover multispecific T-cell engagers for autoimmune diseases and other conditions. AbCellera will lead early discovery on its proprietary TCE platform while Vertex funds all research and development and holds rights to develop and commercialize resulting antibodies, paying AbCellera $28 million upfront plus preclinical, development, regulatory and commercial milestone payments and tiered sales royalties.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- Vertex withdraws EU filings for toddler CF drugsSunday, September 20, 2026
- Court says Vertex Casgevy fertility perk is a kickbackSaturday, September 5, 2026
- Vertex closes $10 billion Crinetics acquisitionWednesday, September 2, 2026
- Crinetics shareholders approve Vertex's $10 billion buyoutTuesday, September 1, 2026